세계의 감마나이프 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

Persistence Market Research has recently published an in-depth report on the global gamma knife market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and medical device sectors focused on non-invasive neurosurgical treatments.

Key Insights:

• Global Market Revenue (2022): US$ 204.1 Million
• Estimated Market Value (2033): US$ 311.4 Million
• Global Market Growth Rate (CAGR 2022-2033): 4.8%

Global Gamma Knife Market - Report Scope:

The gamma knife market focuses on the production, distribution, and use of gamma knife machines, a non-invasive surgical tool primarily used for treating brain tumors, vascular malformations, and other neurological disorders. This market encompasses a range of products and services aimed at improving patient outcomes through precision radiosurgery, which allows for the treatment of complex brain conditions with minimal impact on surrounding healthy tissues.

Market Growth Drivers:

Rising Prevalence of Brain Tumors Coupled with Introduction of Various Combination Treatment Therapies

The rising incidence of brain tumors, coupled with advancements in treatment modalities, is driving the growth of the gamma knife market. According to the American Cancer Society, brain tumors are the eighth most prevalent type of cancer and the third leading cause of cancer deaths in people aged 40 and older. As the global population ages and expands, the demand for effective brain tumor treatments, including gamma knife radiosurgery, is expected to increase.

Gamma knife radiosurgery offers a highly targeted treatment option that spares surrounding healthy brain tissue, making it particularly suitable for patients with multiple brain metastases. The combination of gamma knife radiosurgery with biological and immunological agents is also gaining traction. For example, Elekta's combination therapy for melanoma brain metastases, which pairs immunotherapy with gamma knife radiosurgery, has shown improved tumor control and patient survival, highlighting the potential for combination treatments to drive market growth.

Regulatory Approvals and New Product Launches

The gamma knife market is further supported by regulatory approvals and the introduction of innovative products. For instance, Elekta introduced the Icon in May 2022, a gamma knife system that revolutionized the field by offering frameless, mask-based radiosurgery. This system has been particularly impactful in regions like Australia, where it has expanded the brain SRS capacity for treating neurological diseases, boosting market growth.

Market Challenges:

High Cost of Gamma Knife Radiotherapy Machines Coupled with Low Awareness of Patients

One of the significant challenges facing the gamma knife market is the high cost of gamma knife machines and the associated investment and maintenance expenses. The initial cost of gamma knife machines is considerably higher than other radiation equipment, which limits adoption in emerging economies. For instance, gamma knife surgery in India starts at USD 6,500, while in Western countries, the price ranges from USD 40,000 to USD 70,000. Additionally, the cobalt-60 radiation source used in gamma knife machines costs between USD 1 million to USD 2 million and requires replacement every five years, contributing to the overall expense.

The market's growth is also hindered by the limited availability of gamma knife machines outside of the Americas and Europe, as well as a shortage of skilled professionals capable of operating the equipment. Furthermore, general awareness of gamma knife treatment remains low, with many patients either unaware of the benefits or harboring misconceptions about the procedure. This lack of awareness and understanding is expected to slow down the market's growth, particularly in regions with limited access to advanced healthcare technologies.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the global gamma knife market?
• Which consumer segments are leading the adoption of gamma knife treatments?
• How are advancements in radiosurgery technology influencing the competitive landscape?
• Who are the key players in the global gamma knife market, and what strategies are they employing to maintain their market position?
• What are the emerging trends and future prospects in the global gamma knife market?

Competitive Intelligence and Business Strategy:

Leading players in the global gamma knife market, such as Elekta AB, Varian Medical Systems, and Accuray Incorporated, are focusing on product innovation, strategic collaborations, and expanding their geographical presence to maintain a competitive edge. These companies are investing heavily in research and development to create advanced gamma knife systems that offer improved precision and patient outcomes. Collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of these technologies. Additionally, targeted marketing and educational campaigns are crucial for increasing patient awareness and acceptance of gamma knife treatments.

Key Companies Profiled:

• Elekta AB
• Varian Medical Systems
• Huiheng Medical, Inc.
• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
• Akesis Inc.
• Cyber Medical Corporation Limited.
• Masep Infini Global, Inc.
• Nordion, Inc.
• Hokai
• ET Medical Group
• American Shared Hospital Services

Key Segments Covered in Gamma Knife Industry Research

Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

Organ Treated:

• Head
• Neck
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Technology Roadmap
• 1.5. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption / Usage Analysis
• 4.2. Product USPs / Features
• 4.3. Install Base Scenario
• 4.4. Technology Assessment
• 4.5. Regulatory Landscape
• 4.6. PESTLE Analysis
• 4.7. Porter Analysis
• 4.8. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Radiotherapy Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Prevalence of Obesity
  • 5.2.2. Demand for Non-Invasive Procedures
  • 5.2.3. Growing Burden of Brain Cancer
  • 5.2.4. Increasing Instances of Neurological Disorders
  • 5.2.5. Introduction of Novel Treatment Options
  • 5.2.6. Technological Advancements
  • 5.2.7. Product Adoption Rate
  • 5.2.8. Growing Installed Base
• 5.3. Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis - Impact Assessment

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Disease Indication
  • 6.1.2. By Organ Treated
  • 6.1.3. By Region
• 6.2. 2024 Market Scenario

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Indication

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Indication, 2024-2032
  • 8.3.1. Brain Metastasis
  • 8.3.2. Cancer
  • 8.3.3. Arteriovenous Malformation (AVM)
  • 8.3.4. Trigeminal Neuralgia
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis By Disease Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2032, By Organ Treated

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Organ Treated, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Organ Treated, 2024-2032
  • 9.3.1. Head
  • 9.3.2. Neck
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis By Organ Treated

10. Global Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. South Asia
  • 10.3.5. East Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2019-2023 and Forecast 2024-2032

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Disease Indication
  • 11.3.3. By Organ Treated
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Disease Indication
  • 11.4.3. By Organ Treated
• 11.5. Country Level Analysis & Forecast
  • 11.5.1. U.S. Market Analysis
    • 11.5.1.1. Introduction
    • 11.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.5.1.2.1. By Disease Indication
      • 11.5.1.2.2. By Organ Treated
  • 11.5.2. Canada Market Analysis
    • 11.5.2.1. Introduction
    • 11.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.5.2.2.1. By Disease Indication
      • 11.5.2.2.2. By Organ Treated
• 11.6. Market Trends
• 11.7. Key Market Participants - Intensity Mapping
• 11.8. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 12.3.1. By Country
    • 12.3.1.1. Brazil
    • 12.3.1.2. Mexico
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Disease Indication
  • 12.3.3. By Organ Treated
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Disease Indication
  • 12.4.3. By Organ Treated
• 12.5. Country Level Analysis & Forecast
  • 12.5.1. Brazil Market Analysis
    • 12.5.1.1. Introduction
    • 12.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.1.2.1. By Disease Indication
      • 12.5.1.2.2. By Organ Treated
  • 12.5.2. Mexico Market Analysis
    • 12.5.2.1. Introduction
    • 12.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.2.2.1. By Disease Indication
      • 12.5.2.2.2. By Organ Treated
  • 12.5.3. Argentina Market Analysis
    • 12.5.3.1. Introduction
    • 12.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.5.3.2.1. By Disease Indication
      • 12.5.3.2.2. By Organ Treated
• 12.6. Market Trends
• 12.7. Key Market Participants - Intensity Mapping
• 12.8. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. France
    • 13.3.1.3. Italy
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. Russia
    • 13.3.1.7. BENELUX
    • 13.3.1.8. Nordic Countries
    • 13.3.1.9. Rest of Europe
  • 13.3.2. By Disease Indication
  • 13.3.3. By Organ Treated
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Disease Indication
  • 13.4.3. By Organ Treated
• 13.5. Country Level Analysis & Forecast
  • 13.5.1. Germany Market Analysis
    • 13.5.1.1. Introduction
    • 13.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.1.2.1. By Disease Indication
      • 13.5.1.2.2. By Organ Treated
  • 13.5.2. France Market Analysis
    • 13.5.2.1. Introduction
    • 13.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.2.2.1. By Disease Indication
      • 13.5.2.2.2. By Organ Treated
  • 13.5.3. Italy Market Analysis
    • 13.5.3.1. Introduction
    • 13.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.3.2.1. By Disease Indication
      • 13.5.3.2.2. By Organ Treated
  • 13.5.4. U.K. Market Analysis
    • 13.5.4.1. Introduction
    • 13.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.4.2.1. By Disease Indication
      • 13.5.4.2.2. By Organ Treated
  • 13.5.5. Spain Market Analysis
    • 13.5.5.1. Introduction
    • 13.5.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.5.2.1. By Disease Indication
      • 13.5.5.2.2. By Organ Treated
  • 13.5.6. Russia Market Analysis
    • 13.5.6.1. Introduction
    • 13.5.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.6.2.1. By Disease Indication
      • 13.5.6.2.2. By Organ Treated
  • 13.5.7. Nordic Countries Market Analysis
    • 13.5.7.1. Introduction
    • 13.5.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.7.2.1. By Disease Indication
      • 13.5.7.2.2. By Organ Treated
  • 13.5.8. BENELUX Market Analysis
    • 13.5.8.1. Introduction
    • 13.5.8.2. Market Analysis and Forecast by Market Taxonomy
      • 13.5.8.2.1. By Disease Indication
      • 13.5.8.2.2. By Organ Treated
• 13.6. Market Trends
• 13.7. Key Market Participants - Intensity Mapping
• 13.8. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. India
    • 14.3.1.2. Thailand
    • 14.3.1.3. Indonesia
    • 14.3.1.4. Malaysia
    • 14.3.1.5. Rest of South Asia
  • 14.3.2. By Disease Indication
  • 14.3.3. By Organ Treated
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Disease Indication
  • 14.4.3. By Organ Treated
• 14.5. Country Level Analysis & Forecast
  • 14.5.1. India Market Analysis
    • 14.5.1.1. Introduction
    • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.1.2.1. By Disease Indication
      • 14.5.1.2.2. By Organ Treated
  • 14.5.2. Thailand Market Analysis
    • 14.5.2.1. Introduction
    • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.2.2.1. By Disease Indication
      • 14.5.2.2.2. By Organ Treated
  • 14.5.3. Indonesia Market Analysis
    • 14.5.3.1. Introduction
    • 14.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.3.2.1. By Disease Indication
      • 14.5.3.2.2. By Organ Treated
  • 14.5.4. Malaysia Market Analysis
    • 14.5.4.1. Introduction
    • 14.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 14.5.4.2.1. By Disease Indication
      • 14.5.4.2.2. By Organ Treated
• 14.6. Market Trends
• 14.7. Key Market Participants - Intensity Mapping
• 14.8. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Disease Indication
  • 15.3.3. By Organ Treated
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Disease Indication
  • 15.4.3. By Organ Treated
• 15.5. Country Level Analysis & Forecast
  • 15.5.1. China Market Analysis
    • 15.5.1.1. Introduction
    • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.1.2.1. By Disease Indication
      • 15.5.1.2.2. By Organ Treated
  • 15.5.2. Japan Market Analysis
    • 15.5.2.1. Introduction
    • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.2.2.1. By Disease Indication
      • 15.5.2.2.2. By Organ Treated
  • 15.5.3. South Korea Market Analysis
    • 15.5.3.1. Introduction
    • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.5.3.2.1. By Disease Indication
      • 15.5.3.2.2. By Organ Treated
• 15.6. Market Trends
• 15.7. Key Market Participants - Intensity Mapping
• 15.8. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Disease Indication
  • 16.3.3. By Organ Treated
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Disease Indication
  • 16.4.3. By Organ Treated
• 16.5. Country Level Analysis & Forecast
  • 16.5.1. Australia Market Analysis
    • 16.5.1.1. Introduction
    • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.1.2.1. By Disease Indication
      • 16.5.1.2.2. By Organ Treated
  • 16.5.2. New Zealand Market Analysis
    • 16.5.2.1. Introduction
    • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.5.2.2.1. By Disease Indication
      • 16.5.2.2.2. By Organ Treated
• 16.6. Market Trends
• 16.7. Key Market Participants - Intensity Mapping
• 16.8. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkiye
    • 17.3.1.3. Northern Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Disease Indication
  • 17.3.3. By Organ Treated
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Disease Indication
  • 17.4.3. By Organ Treated
• 17.5. Country Level Analysis & Forecast
  • 17.5.1. GCC Countries Market Analysis
    • 17.5.1.1. Introduction
    • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.1.2.1. By Disease Indication
      • 17.5.1.2.2. By Organ Treated
  • 17.5.2. Turkiye Market Analysis
    • 17.5.2.1. Introduction
    • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.2.2.1. By Disease Indication
      • 17.5.2.2.2. By Organ Treated
  • 17.5.3. Northern Africa Market Analysis
    • 17.5.3.1. Introduction
    • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.3.2.1. By Disease Indication
      • 17.5.3.2.2. By Organ Treated
  • 17.5.4. South Africa Market Analysis
    • 17.5.4.1. Introduction
    • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.5.4.2.1. By Disease Indication
      • 17.5.4.2.2. By Organ Treated
• 17.6. Market Trends
• 17.7. Key Market Participants - Intensity Mapping
• 17.8. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Share Analysis of Top Players
• 18.3. Market Presence Analysis

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Benchmarking
• 19.3. Competition Deep Dive
  • 19.3.1. Elekta AB
    • 19.3.1.1. Overview
    • 19.3.1.2. Disease Indication Portfolio
    • 19.3.1.3. Key Financials
    • 19.3.1.4. Sales Footprint
    • 19.3.1.5. SWOT Analysis
    • 19.3.1.6. Strategy Overview
      • 19.3.1.6.1. Marketing Strategy
      • 19.3.1.6.2. Product Strategy
      • 19.3.1.6.3. Channel Strategy
  • 19.3.2. Varian Medical Systems
    • 19.3.2.1. Overview
    • 19.3.2.2. Disease Indication Portfolio
    • 19.3.2.3. Key Financials
    • 19.3.2.4. Sales Footprint
    • 19.3.2.5. SWOT Analysis
    • 19.3.2.6. Strategy Overview
      • 19.3.2.6.1. Marketing Strategy
      • 19.3.2.6.2. Product Strategy
      • 19.3.2.6.3. Channel Strategy
  • 19.3.3. Huiheng Medical, Inc.
    • 19.3.3.1. Overview
    • 19.3.3.2. Disease Indication Portfolio
    • 19.3.3.3. Key Financials
    • 19.3.3.4. Sales Footprint
    • 19.3.3.5. SWOT Analysis
    • 19.3.3.6. Strategy Overview
      • 19.3.3.6.1. Marketing Strategy
      • 19.3.3.6.2. Product Strategy
      • 19.3.3.6.3. Channel Strategy
  • 19.3.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
    • 19.3.4.1. Overview
    • 19.3.4.2. Disease Indication Portfolio
    • 19.3.4.3. Key Financials
    • 19.3.4.4. Sales Footprint
    • 19.3.4.5. SWOT Analysis
    • 19.3.4.6. Strategy Overview
      • 19.3.4.6.1. Marketing Strategy
      • 19.3.4.6.2. Product Strategy
      • 19.3.4.6.3. Channel Strategy
  • 19.3.5. Akesis Inc.
    • 19.3.5.1. Overview
    • 19.3.5.2. Disease Indication Portfolio
    • 19.3.5.3. Key Financials
    • 19.3.5.4. Sales Footprint
    • 19.3.5.5. SWOT Analysis
    • 19.3.5.6. Strategy Overview
      • 19.3.5.6.1. Marketing Strategy
      • 19.3.5.6.2. Product Strategy
      • 19.3.5.6.3. Channel Strategy
  • 19.3.6. Cyber Medical Corporation Limited.
    • 19.3.6.1. Overview
    • 19.3.6.2. Disease Indication Portfolio
    • 19.3.6.3. Key Financials
    • 19.3.6.4. Sales Footprint
    • 19.3.6.5. SWOT Analysis
    • 19.3.6.6. Strategy Overview
      • 19.3.6.6.1. Marketing Strategy
      • 19.3.6.6.2. Product Strategy
      • 19.3.6.6.3. Channel Strategy
  • 19.3.7. Masep Infini Global, Inc.
    • 19.3.7.1. Overview
    • 19.3.7.2. Disease Indication Portfolio
    • 19.3.7.3. Key Financials
    • 19.3.7.4. Sales Footprint
    • 19.3.7.5. SWOT Analysis
    • 19.3.7.6. Strategy Overview
      • 19.3.7.6.1. Marketing Strategy
      • 19.3.7.6.2. Product Strategy
      • 19.3.7.6.3. Channel Strategy
  • 19.3.8. Nordion, Inc.
    • 19.3.8.1. Overview
    • 19.3.8.2. Disease Indication Portfolio
    • 19.3.8.3. Key Financials
    • 19.3.8.4. Sales Footprint
    • 19.3.8.5. SWOT Analysis
    • 19.3.8.6. Strategy Overview
      • 19.3.8.6.1. Marketing Strategy
      • 19.3.8.6.2. Product Strategy
      • 19.3.8.6.3. Channel Strategy
  • 19.3.9. Hokai
    • 19.3.9.1. Overview
    • 19.3.9.2. Disease Indication Portfolio
    • 19.3.9.3. Key Financials
    • 19.3.9.4. Sales Footprint
    • 19.3.9.5. SWOT Analysis
    • 19.3.9.6. Strategy Overview
      • 19.3.9.6.1. Marketing Strategy
      • 19.3.9.6.2. Product Strategy
      • 19.3.9.6.3. Channel Strategy
  • 19.3.10. ET Medical Group
    • 19.3.10.1. Overview
    • 19.3.10.2. Disease Indication Portfolio
    • 19.3.10.3. Key Financials
    • 19.3.10.4. Sales Footprint
    • 19.3.10.5. SWOT Analysis
    • 19.3.10.6. Strategy Overview
      • 19.3.10.6.1. Marketing Strategy
      • 19.3.10.6.2. Product Strategy
      • 19.3.10.6.3. Channel Strategy
  • 19.3.11. American Shared Hospital Services
    • 19.3.11.1. Overview
    • 19.3.11.2. Disease Indication Portfolio
    • 19.3.11.3. Key Financials
    • 19.3.11.4. Sales Footprint
    • 19.3.11.5. SWOT Analysis
    • 19.3.11.6. Strategy Overview
      • 19.3.11.6.1. Marketing Strategy
      • 19.3.11.6.2. Product Strategy
      • 19.3.11.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology